Why the study?
What are the pharmacokinetic and pharmacodynamic properties of irbesartan compared to other angiotensin II receptor antagonists?
Comparison
Irbesartan (angiotensin II receptor antagonist) vs Other angiotensin II receptor antagonists
Design
Review
Authors
Loading...
Favorable PK profile may guide irbesartan dosing; leaves open comparative outcome trials versus other ARBs.
What are the pharmacokinetic and pharmacodynamic properties of irbesartan compared to other angiotensin II receptor antagonists?
Irbesartan demonstrates favorable pharmacokinetic properties, including high bioavailability, long half-life, and minimal drug interactions, which may offer clinical advantages over other angiotensin II receptor antagonists.
H. Brünner (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: